RYTM Key Statistics, Chart & Performance
The current stock price of RYTM is 104.63 USD. In the past month the price decreased by -0.34%. In the past year, price increased by 77.67%.
RYTM Latest News, Press Relases and Analysis
RYTM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.36 | 406.92B | ||
| AMGN | AMGEN INC | 15.79 | 186.00B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.09B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.68 | 117.51B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.08 | 76.06B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 928.02 | 62.53B | ||
| INSM | INSMED INC | N/A | 44.10B | ||
| NTRA | NATERA INC | N/A | 32.88B | ||
| BIIB | BIOGEN INC | 10.8 | 26.52B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.23 | 20.71B | ||
| INCY | INCYTE CORP | 15.81 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.21B |
Related stock screener links
About RYTM
Company Profile
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The company is headquartered in Boston, Massachusetts and currently employs 283 full-time employees. The company went IPO on 2017-10-05. The firm is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
Company Info
RHYTHM PHARMACEUTICALS INC
222 Berkeley Street, 12th Floor
Boston MASSACHUSETTS 02116 US
CEO: David P. Meeker
Employees: 283
Phone: 18572644280
RHYTHM PHARMACEUTICALS INC / RYTM FAQ
What does RYTM do?
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The company is headquartered in Boston, Massachusetts and currently employs 283 full-time employees. The company went IPO on 2017-10-05. The firm is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
What is the current price of RYTM stock?
The current stock price of RYTM is 104.63 USD. The price increased by 3.2% in the last trading session.
Does RHYTHM PHARMACEUTICALS INC pay dividends?
RYTM does not pay a dividend.
What is the ChartMill technical and fundamental rating of RYTM stock?
RYTM has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
On which exchange is RYTM stock listed?
RYTM stock is listed on the Nasdaq exchange.
Can you provide the growth outlook for RHYTHM PHARMACEUTICALS INC?
The Revenue of RHYTHM PHARMACEUTICALS INC (RYTM) is expected to grow by 46.81% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the ownership details for RYTM stock?
You can find the ownership structure of RHYTHM PHARMACEUTICALS INC (RYTM) on the Ownership tab.
RYTM Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to RYTM. When comparing the yearly performance of all stocks, RYTM is one of the better performing stocks in the market, outperforming 91.9% of all stocks.
RYTM Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RYTM. RYTM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
RYTM Financial Highlights
Over the last trailing twelve months RYTM reported a non-GAAP Earnings per Share(EPS) of -3.1. The EPS increased by 30.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.01% | ||
| ROE | -66.87% | ||
| Debt/Equity | 0.35 |
RYTM Forecast & Estimates
20 analysts have analysed RYTM and the average price target is 127.65 USD. This implies a price increase of 22% is expected in the next year compared to the current price of 104.63.
For the next year, analysts expect an EPS growth of 31.72% and a revenue growth 46.81% for RYTM